Breast
Primary Site | Histology |
---|---|
C500-C506, C508-C509 | 8000-8700, 8982-8983 |
C501-C506, C508-C509 | 8720-8790 |
Notes
8000-8700, 8720-8790 [except C500], 8982-8983 C500 Nipple C501 Central portion of breast C502 Upper-inner quadrant of breast C503 Lower-inner quadrant of breast C504 Upper-outer quadrant of breast C505 Lower-outer quadrant of breast C506 Axillary Tail of breast C508 Overlapping lesion of breast C509 Breast, NOS **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 48 *Breast*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schemas for the listed histologies * 8720-8790: *Melanoma Skin* (C500 only) * 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8981, 8990, 9000-9016, 9030-9043, 9045-9138, 9141-9230, 9240-9580, 9582: *Soft Tissue Trunk and Extremities* * 8804-8806, 8930-8931, 8991, 9020, 9044, 9231, 9581: *Soft Tissue Rare* * 8935-8936: *GIST* * 8992: *Soft Tissue Other* * 9140: *Kaposi Sarcoma* * 9700-9701: *Mycosis Fungoides* **Note 3:** In addition to coding *EOD Primary Tumor, EOD Regional Nodes* and *EOD Mets*, the following data items are also needed to assign a stage group for Breast. * ER Summary * PR Summary * HER2 Summary * Oncotype Dx Recurrence ScoreData Items
Name | Default Value | Used for Staging | NAACCR Item | Required By | Metadata |
---|---|---|---|---|---|
Year of Diagnosis | <BLANK> | No |
NAACCR #390
dateOfDiagnosis |
None | |
Primary Site | <BLANK> | Yes |
NAACCR #400
primarySite |
None | |
Histology | <BLANK> | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | |
Behavior | <BLANK> | Yes |
NAACCR #523
behaviorCodeIcdO3 |
None | |
Tumor Size Clinical | <BLANK> | No |
NAACCR #752
tumorSizeClinical |
None | |
Tumor Size Pathological | <BLANK> | No |
NAACCR #754
tumorSizePathologic |
None | |
Tumor Size Summary | 999 | Yes |
NAACCR #756
tumorSizeSummary |
None | |
Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
Sentinel Lymph Nodes Positive | 99 | No |
NAACCR #835
sentinelLymphNodesPositive |
None | |
Sentinel Lymph Nodes Examined | 99 | No |
NAACCR #834
sentinelLymphNodesExamined |
None | |
RX Summ Surgery/Radiation Sequence | <BLANK> | No |
NAACCR #1380
rxSummSurgRadSeq |
None | |
RX Summ Systemic/Surgery Sequence | <BLANK> | No |
NAACCR #1639
rxSummSystemicSurSeq |
None | |
EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
EOD Regional Nodes | 999 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
EOD Mets | 00 | Yes |
NAACCR #776
eodMets |
None | |
SS2018 | <BLANK> | No |
NAACCR #764
summaryStage2018 |
None | |
Grade Clinical | 9 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
Grade Pathological | 9 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
Grade Post Therapy Clin (yc) | <BLANK> | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI |
Grade Post Therapy Path (yp) | <BLANK> | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI |
Lymph Nodes Positive Axillary Level I-II | X8 | Yes |
NAACCR #3882
lnPositiveAxillaryLevel1To2 |
All | SSDI |
ER Summary | 9 | Yes |
NAACCR #3827
estrogenReceptorSummary |
All | SSDI |
ER Percent Positive | XX8 | No |
NAACCR #3826
estrogenReceptorPercntPosOrRange |
COC SEER (RC) |
SSDI |
ER Allred Score | X8 | No |
NAACCR #3828
estrogenReceptorTotalAllredScore |
COC 2018–2022 SEER (RC) 2018–2022 |
SSDI 2018–2022 |
PR Summary | 9 | Yes |
NAACCR #3915
progesteroneRecepSummary |
All | SSDI |
PR Percent Positive | XX8 | No |
NAACCR #3914
progesteroneRecepPrcntPosOrRange |
COC SEER (RC) |
SSDI |
PR Allred Score | X8 | No |
NAACCR #3916
progesteroneRecepTotalAllredScor |
COC 2018–2022 SEER (RC) 2018–2022 |
SSDI 2018–2022 |
HER2 Overall Summary | 9 | Yes |
NAACCR #3855
her2OverallSummary |
All | SSDI |
HER2 IHC Summary | 8 | No |
NAACCR #3850
her2IhcSummary |
CCCR/Canada 2018–2020 COC 2018–2020 SEER (RC) 2018–2020 |
SSDI |
HER2 ISH Summary | 8 | No |
NAACCR #3854
her2IshSummary |
CCCR/Canada 2018–2020 COC 2018–2020 SEER (RC) 2018–2020 |
SSDI |
HER2 ISH DP Ratio | XX.8 | No |
NAACCR #3852
her2IshDualProbeRatio |
COC 2018–2020 SEER (RC) 2018–2020 |
SSDI |
HER2 ISH DP Copy No | XX.8 | No |
NAACCR #3851
her2IshDualProbeCopyNumber |
COC 2018–2020 SEER (RC) 2018–2020 |
SSDI |
HER2 ISH SP Copy No | XX.8 | No |
NAACCR #3853
her2IshSingleProbeCopyNumber |
COC 2018–2020 SEER (RC) 2018–2020 |
SSDI |
Ki-67 (MIB-1) | XXX.8 | No |
NAACCR #3863
ki67 |
COC SEER (RC) |
SSDI |
Oncotype DX Recur Score - Invasive | XX9 | Yes |
NAACCR #3904
oncotypeDxRecurrenceScoreInvasiv |
All | SSDI |
Oncotype Dx Risk Level - Invasive | 8 | No |
NAACCR #3906
oncotypeDxRiskLevelInvasive |
COC SEER (RC) |
SSDI |
Oncotype DX Recur Score - DCIS | XX8 | No |
NAACCR #3903
oncotypeDxRecurrenceScoreDcis |
COC SEER (RC) |
SSDI |
Oncotype Dx Risk Level - DCIS | 8 | No |
NAACCR #3905
oncotypeDxRiskLevelDcis |
COC SEER (RC) |
SSDI |
Multigene Signature Method | 8 | No |
NAACCR #3894
multigeneSignatureMethod |
COC SEER |
SSDI |
Multigene Signature Result | X8 | No |
NAACCR #3895
multigeneSignatureResults |
COC SEER |
SSDI |
Response Neoadjuv Therapy | 8 | No |
NAACCR #3922
responseToNeoadjuvantTherapy |
COC SEER (RC) |
SSDI |
Initial Context
Outputs
Name | Default Value | Description | NAACCR Item | Metadata |
---|---|---|---|---|
Schema ID | 00480 |
NAACCR #3800
schemaId |
None | |
Derived Version | {{ctx_alg_version}} | None | None | |
Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None | |
Derived Summary Grade 2018 | <BLANK> |
NAACCR #1975
derivedSummaryGrade2018 |
None |